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10.1126/sciaCandida albicans is a pathogenic yeast that causesmucosal and systematic infectionswith highmortality. The absence
of facile molecular genetics has been a major impediment to analysis of pathogenesis. The lack of meiosis coupled
with the absence of plasmids makes genetic engineering cumbersome, especially for essential functions and gene
families. We describe a C. albicans CRISPR system that overcomesmany of the obstacles to genetic engineering in this
organism. The high frequency with which CRISPR-induced mutations can be directed to target genes enables easy
isolationof homozygousgeneknockouts, evenwithout selection.Moreover, the systempermits the creationof strains
withmutations inmultiple genes, gene families, and genes that encode essential functions. This CRISPR system is also
effective in a fresh clinical isolate of undetermined ploidy. Our method transforms the ability to manipulate the ge-
nome of Candida and provides a new window into the biology of this pathogen.INTRODUCTION
Candida albicans, the major fungal pathogen of humans, causes infec-
tions that can be fatal in immunocompromised individuals (1–3). The
absence of facile molecular genetics has been a major impediment to
analysis of pathogenesis. Candida is diploid, lacks any known meiotic
phase, and has no plasmid system. Diploidy is a problem because ob-
taining a phenotype for a recessive mutation requires engineering the
mutation in both alleles of a gene. In the absence of meiosis and plas-
mids, diploidy makes it difficult to investigate genes encoding vital
functions. In more tractable organisms, loss-of-function mutations in
essential genes can be maintained in a diploid and identified after mei-
osis. Alternatively, they can bemaintained inmutant strainswith a plas-
mid carrying a functional copy. The difficulty in making multiple
knockouts becomes insurmountable when analyzing gene families,
where simultaneous mutation at multiple loci is required for a pheno-
type. The Candida genome is populated by many gene families, includ-
ing more than 120 drug efflux pumps (4–6). This redundancy impedes
analysis of the resistance to antifungal agents because the construction
of multiple mutations in the members of these families is beyond cur-
rent technology. These pumps also give Candida a high inherent drug
resistance, rendering all but one drug resistance marker useless.
An added complexity to genetics inCandida is that the chromosome
number is not rigidly controlled, so that many strains contain one or
more additional copies of a chromosome (2n+1) (7–10). Such variation
in chromosome number can amplify the difficulty in achieving a homo-
zygous recessive mutation. Moreover, it is a serious hurdle to the anal-
ysis of fresh clinical isolates, which can have multiple aneuploidies (8).
Although isolates of different ploidy have been described, they are un-
stable and mostly revert to the diploid state (11).
We have developed a CRISPR system in C. albicans that overcomes
many of these roadblocks by permitting efficient genome editing. Our
system, shown in Fig. 1D, consists of a Candida-compatible Cas9 nu-
clease and a synthetic guide RNA (sgRNA) that directs Cas9 to cleave
regions in the genome that hybridize to the 20–base pair (bp) guide (or
protospacer) from the sgRNAwhen it is followed by the sequenceNGG
(PAMor the protospacer adjacentmotif). This systemhas been success-1Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA. 2Department of
Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
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animals [reviewed in (12, 13)]. However, most of these systems do
not pose the unique set of constraints found in Candida.
The CRISPR system we have constructed in Candida provides an
efficient method for generating homozygous mutations of a target gene
in one transformation in both laboratory and clinical isolates.Moreover,
in a single transformation, it is possible to obtain homozygous muta-
tions of multiple familymembers or in genes of vital function. The abil-
ity to analyze essential genes provides an opportunity to explore
potential antifungal targets. Computational analysis shows that most
genes in the Candida genome can be uniquely targeted by our system.RESULTS
A CRISPR system for Candida
To create a CRISPR system for Candida, several challenges had to be
overcome: the Cas9 gene had to be recoded because the leucine CUG
codon is predominantly translated as serine, there are no autonomously
replicating plasmids, and there are no expression systems for small
RNAs. To express a Candida-compatible Cas9, we synthesized a
Candida/Saccharomyces codon–optimized version ofCas9 (CaCas9)
that avoids the use of the CUG codon, ensuring compatibility with all
CTG clade species. The Cas9 gene is fused to sequences encoding the
SV40 nuclear localization signal and FLAG tag for in-frame fusion to
the 3′ end of the gene. The Cas9 from this construct is expressed from
the constitutive ENO1 promoter at the plasmid integration site. Because
there are no autonomously replicating plasmids in Candida, we
integrated this construct by transformation into SC5314 at the ENO1
locus. The RNA polymerase III (Pol III) promoter SNR52 was used
to express sgRNAs necessary for Cas9 targeting.
Formost genes,Candida diploids require knockout of both alleles of
a gene to obtain a phenotype. As a proof of principle for our Candida
CRISPR system, we chose to target ADE2 because the ade2 mutation
confers an easily visible red phenotype. The red ade2 phenotype isman-
ifest among whiteADE2/ADE2 diploids only if both alleles of theADE2
gene are simultaneously nonfunctional (ade2/ade2).
We created two systems based on the design principles listed above.
The “Duet system,” shown inFig. 1A, requires the sequential integration
of two plasmids. Integration of the CaCas9 expression plasmid at the1 of 6
R E S EARCH ART I C L EENO1 locus is first selected with nourseothricin (Nat). By induction of
the flippase gene and subsequent excision of theNatR gene, it is possible
to use this marker again for selection. The second plasmid for expres-
sion of the sgRNA againstADE2 (targeted to theRP10 locus) is cotrans-
formed with a mutagenic double-stranded oligonucleotide. This
oligonucleotide is complementary to ADE2 and contains a mutation
to the PAM sequence and a premature UAA stop codon (sequences
shown in Fig. 2B). No defect in the growth rate of Cas9-expressing
strains was detected on YPD medium (see Materials and Methods).
The “Solo system” (Fig. 1B) consolidates the CRISPR system with the
sgRNA system by fusing them in a single plasmid construct that is then
integrated at the ENO1 locus. The systems described here permit effi-
cient mutagenesis using a guide RNA, whose introduction is selected
using the Nat resistance marker. Targeting additional genes would re-
quire the introduction of additional guides. To this end, we created a
version of the Solo plasmid with a recyclable Nat cassette (fig. S1) that
permits the introductionof additional guide sequences to target other loci.
Both the Duet and Solo systems feature simplified ligation of annealedVyas, Barrasa, Fink Sci. Adv. 2015;1:e1500248 3 April 2015oligos into the site created with BsmBI, leaving no extraneous sequences
(Fig. 1C).
Highly efficient CRISPR mutagenesis in Candida
Both the Duet and Solo systems produce red ade2/ade2 transformants
at high frequency (Fig. 2A and figs. S2A and S3B); each required a func-
tional Cas9, an sgRNA against ADE2, and the complementary repair
template spanning the cut site. In the absence of any one of these com-
ponents, only white ADE2+ colonies were obtained (figs. S2 and S3).
The Duet system produced 20 to 40% red colonies among the transfor-
mants, and thesewere authenticCRISPR-inducedmutations, as sequenc-
ing of the ade2/ade2mutants revealed the UAA and the PAMmutation
in the ade2 gene (Fig. 2B). The Solo system was more efficient than the
Duet system; 60 to 80%of the transformants were red ade2/ade2mutants
(Fig. 2A and fig. S3B). The frequency of targeting was so high that
transformationwith Solo plasmid and the repair template for ade2without
any selection for integration of either the Solo Cas9 cassette or the repair
template yielded red ade2/ade2mutants at a rate of 2 to 3% (fig. S3D).The Solo system appears to be general-
ly applicable for mutagenesis, because we
were able to easily create mutations or
truncations in URA3, RAS1,MtlA1,Mtla2,
and TPK2 (Fig. 2 and Fig. S4). Transforma-
tion plates for RAS1V13 mutants provided
an easy visual phenotype for identification
based on colony morphology or glycogen
staining with iodine (Fig. 2D). Our isolation
ofRAS1 truncationmutants is particular-
ly significant, because this mutation sig-
nificantly reduces the growth rate (Fig. 2E)
(14). From our transformation plates, we
obtained slow-growing isolates at a similar
frequency to that of wrinkly colonies for
RAS1V13.
The high efficiency of the Candida
CRISPR system in making homozygous
knockouts suggested that it might be pos-
sible to knock outmultiple members of a
gene family with a single guide. To test
this possibility, we attempted to knock
out both CDR1 and CDR2, members of
the multigene drug efflux pump encoding
family. Loss of cdr1 or cdr2 increases sen-
sitivity to the clinically useful azole anti-
fungal agents (15). To this end, we designed
an sgRNA that targeted both genes and a re-
pair template that had homology to both
CDR1 and CDR2. Our repair template con-
tained a stop codon as well as a unique re-
striction site, which enabled us to quickly
genotype transformants (Fig. 3A). Among
the transformants,we identifieddrug-sensitive
strains that had much greater drug sensi-
tivity than the parent (Fig. 3, B and C, and
fig. S5). Genotyping both by polymerase
chain reaction (PCR) and by sequencing
indicated that these strains were double
mutants of cdr1 and cdr2 (Fig. 3A).R
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Fig. 1. Candida CRISPR expression constructs. (A) Duet system consists of two plasmids, pV1025 (top
before and after flipout), which targets ENO1, and pV1090, which targets RP10. (B) Solo system consists of
one plasmid, pV1093, which targets ENO1. Figures are not drawn to scale. (C) Both Solo and Duet guide
expression systems permit rapid cloning by digestion with BsmBI followed by ligation of annealed oligos
(shaded sequences) with desired guide sequence (ADE2 guide sequence in red box). (D) Schematic of Cas9
mutagenesis method. The system can create homozygous mutations in the gene (*) and simultaneously
mutate sequences (for example, the PAM) to prevent repeated cleavage subsequent to integration.2 of 6
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ficiencywith a single guide.Moreover, it demonstrates that one does not
need a visible phenotype to identify the intended transformants. The
Candida CRISPR system is so efficient that ~20% of the transformants
were drug-sensitive. Thus, evenmutantswithmodest phenotypic differ-
ences from wild type can now be easily identified.
Drug resistance to azoles is a problem in the clinical treatment of
Candida infections. Although several mechanisms contribute to this
resistance [reviewed in (16)], up-regulation of drug pumps is a common
cause. To determine whether ourCDR1/CDR2CRISPR guides could be
used to characterize a recent fluconazole–hyper-resistant clinical isolate
Can90, we transformed this strain with the appropriate guides and re-
pair templates, as we did for SC5314. We easily identified cdr1/cdr1
cdr2/cdr2 homozygous double mutants (three of seven transformants
tested) and showed that these transformants no longer displayed the
hyper-resistance to fluconazole or cycloheximide displayed by the pa-
rental clinical isolate Can90 (Fig. 3B and fig. S5).
The ease of Saccharomyces genetics largely rests on the ability to eas-
ily produce multiple mutations in a given strain. Without the ability to
make recombinant haploids through meiosis, this is a difficult feat toVyas, Barrasa, Fink Sci. Adv. 2015;1:e1500248 3 April 2015achieve in Candida. To see if we could circumvent this limitation with
our CRISPR system, we cotransformed our Solo CDR system alongside
the sgRNA-expressing Duet ADE2 vector. We were able to identify
strains that were simultaneously mutated at ADE2, CDR1, and CDR2
(six loci) from a single transformation (Fig. 3C).
CRISPR to target essential functions
We obtained homozygous loss-of-functionmutations in essential genes of
C. albicans using the CRISPR system by creating conditional alleles. Null
alleles ofDCR1, which is required for ribosomal RNAprocessing, are lethal
at low temperature but viable at high temperature (17). Transformation of
SC5314was carried out using the SoloCRISPRplasmid containing a guide
directed againstDCR1 and a repair template that introduced a stop codon.
The transformation plateswere incubated at 37°C, and transformantswere
screened for growth at either 37° or 16°C to identify candidate dcr1/dcr1
mutants.We isolated a number of dcr1/dcr1mutants that failed to grow at
16°C and contained the signature nonsensemutation (Fig. 4A and fig. S4).
Another approach to obtaining null mutations in lethal functions is
to replace the resident functional genes with the gene under the control
of the inducibleMAL2 promoter. To test if we could quickly introduce aregulatable promoter for SNF1, which is es-
sential (18,19),we created a guide that cut in
the SNF1 promoter region and inserted a
MAL2promoter fragmentwith flankingho-
mology to resident sequences, permitting
SNF1 to be transcribed on maltose but
not glucose. We plated transformation
mixtures onto selective maltose plates, and
replica-plated these onto maltose (permis-
sive) or glucose (restrictive) medium. We
were able to identify several transformants
that only grew in maltose and confirmed
that they were maltose promoter integrants
(Fig. 4B and fig. S6B), verifying the essential
nature of SNF1.
Both previous attempts to knock out
SNF1 function relied on the failure to ob-
tain a homozygous gene replacement
(18, 19)without the presence of SNF1 else-
where in the genome. This indirect evi-
dence suggests that the Snf1 function is
essential and implies that the kinase activ-
ity of Snf1 is required. It does not rule out
the possibility that only the protein itself,
but not the kinase activity, is required.
To discriminate between these possibil-
ities, we generated Solo system guides
for SNF1, and repair templates thatmutate
Lys81 to arginine in the ATP (adenosine
5′-triphosphate)–binding pocket. Muta-
tion at this conserved position either elim-
inates or vastly diminishes kinase activity
in Saccharomyces andhumanSnf1/AMPK
(20, 21). We noticed that our K81R
CRISPR transformation plates contained
~40% wrinkled colonies (fig. S6A), which,
upon further analysis, turned out to be
homozygous for snf1-K81R (fig. S6, BWT
YPD
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Fig. 2. C. albicans CRISPR is an efficientmutagen-
esis system. (A) Candida CRISPR efficiently muta-
genizes both ADE2 loci in SC5314. The transformation
mix containedpV1081andamutagenic repair template
(see Materials and Methods and the Supplementary
Materials). OmissionofCas9, sgRNA, or a repair template
with homology to the guide resulted in failure to obtain ade2mutants. (B) Sequence of the ADE2 locus in wild-
type (WT) and mutant isolates. (C) Assay for ura3/ura3 transformant on 5-fluoroorotic acid (FOA) plates. FOA
permits growth of ura3/ura3 but not URA3+ strains. (D) Wrinkled colony morphology of RAS1V13 on
transformationplates (top) andglycogenaccumulationdefect/wrinkledcolonymorphologyofRAS1V13 (bottom).
Glycogenaccumulation is visualizedbyexposing yeast to iodine vapors,which stainsglycogen red.WT (left) has a
smooth morphology and stains red due to accumulated glycogen (left), whereas RAS1V13 (right) has a wrinkled
morphology and fails to stain. (E) Truncation of RAS1 at position 13 [ras1(TAA)13] reduces growth rate.3 of 6
R E S EARCH ART I C L Eand C). The snf1-K81R/snf1-K81R strains are unable to grow onmaltose
(Fig. 4B), consistent with the Saccharomyces snf1 mutant’s failure to
growonnon-glucose carbon sources (20, 22). The additional phenotypes
of cold sensitivity (Fig. 4C) and defective filamentous growth (Fig. 4D) are
also seen in snf1mutants in Saccharomyces (23–25). In addition, we found
that snf1-K81R was hypersensitive to fluconazole, suggesting that Snf1’s
stress response function is required for activation of fluconazole resistance
(fig. S6).
CRISPR-accessible sites in the genome
We searched the most recent diploid assembly of the C. albicans ge-
nome database (26) for Cas9 recognition motifs—N20 followed by aVyas, Barrasa, Fink Sci. Adv. 2015;1:e1500248 3 April 2015PAM sequence—and selected only those sequences that overlap with
annotated features. Of the 6466 genes in the Candida genome, 6341
can be targeted uniquely by 601,770 guides. Of those guides, 551,175
can direct cleavage at both alleles, whereas 59,595 target only one of
the two. A small subset of these guides target more than one location
in the same gene (genes with internal repeats). The sequences of each of
these guides can be found in the Supplementary Data Files. In addition,
we identified 49,195 guides that target more than one putative gene
sequence, without targeting non-genic sequences. Such sequences can
be found for 6023 genes. These can be used to target certain motifs or
gene families for simultaneous mutagenesis, as we did with CDR1 and
CDR2, and are listed in the Supplementary Data Files.EcoRI
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Fig. 3. CRISPR permits simultaneous targeting
of CDR1 and CDR2, whichmediate resistance to
fluconazole and cycloheximide. (A) Sequence
of CDR1 and CDR2 loci and verification by diges-
tion. (B) Mutation of CDR1 and CDR2 sensitizes
SC5314 (left) and fluconazole-resistant clinical iso-
late Can90 (right) to fluconazole (0.41 mg/ml for
SC5314, 200 mg/ml for Can90). Different flucona-
zole concentrations were used for each strain
background, because the Can90 isolate had much
greater resistance. Solid lines indicate mediumwithout fluconazole, and dotted lines indicate medium with fluconazole. (C) Simultaneous mutation of three genes (six sites) in a single transformation,
and the resulting phenotypes. Left panel is YPD, and right panel is YPD plus cycloheximide at 400 mg/ml. The poorer growth on petri plates of the ade2
cdr1 cdr2 triple mutants is reflected in liquid growth on fluconazole. The ade2 CDR1 CDR2 has a doubling time of 6 hours, whereas the ade2 cdr1 cdr2mutant
has a doubling time of 12 hours when grown in fluconazole (1.2 mg/ml).4 of 6
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The CRISPR system we have developed circumvents many of the chal-
lenges unique to the genetic manipulation of C. albicans. A major im-
pediment has been the paucity of antibiotic resistance markers, which,
coupled with diploidy and variable transformation frequency, makes
knockouts of a single function a considerable task. Our system enables
a single transformation experiment tomutate both copies of a gene or to
delete several copies of a multigene family, resulting in a discernable
phenotype. Furthermore, CRISPR-induced mutations are observed at
such a high frequency that they can be made without selection. Using
a combination of guides, we showed that one can knock out both copies
of three genes, a feat that previously could take several months with no
guarantee of success. Although we had no difficulty in obtaining a high
frequency of mutagenesis in a number of genes, there may be some that
are less tractable.
The high frequency ofCRISPR-inducedmutations enables us to sur-
mount a major roadblock in Candida biology—the identification of es-
sential genes. Previously, a gene could be misconstrued as essential
because low transformation frequencies and poor targeting led to the
failure to obtain homozygous null mutations. However, the efficacy
of CRISPR technology not only overcomes this roadblock but also
permits discrimination among the functions of an essential gene. UsingVyas, Barrasa, Fink Sci. Adv. 2015;1:e1500248 3 April 2015this technology, we were able to obtain the unanticipated result that the
kinase function of SNF1 is not required for its essential function. The
prospect of uncovering all the vital functions inCandida is supported by
our genomic analysis, which revealed that greater than 98% of the genes
are accessible to modification with our CRISPR system. The ability to
identify and analyze essential functions should facilitate the search for
more effective antifungal targets.
The successful implementation of CRISPR in Candida required
the solution of several technical constraints. First, the Cas9 gene had
to be recoded so that it was consonant with the CUG codon divergence
characteristic of theCandida clade. Second, vectors for expression of the
guide RNA required identifying suitable RNAPol III promoters. Not all
of those assayedwere effective. Third, we identified guide sequences that
can differentially target genes in diploid Candida. These include guides
that are allele- and gene-specific and those that could target multiple
genes or gene families. Gene families, which have been historically dif-
ficult to study, can now be modified in a single experiment.
Our finding that CRISPR works effectively in a recent antifungal-
resistant clinical isolate suggests a route to characterize clinical isolates
of drug-resistant strains of Candida. The contribution of each of the
many mechanisms that render Candida resistant to antifungals—
changes in ergosterol biosynthesis, up-regulation of multidrug efflux
and uptake pumps, changes in cell wall composition, and overexpres-
sion or mutation of drug target genes—can now be directly measured
in clinical isolates using appropriate guides.MATERIALS AND METHODS
Strains and media
C. albicans strain SC5314 was used for all experiments unless otherwise
noted. The fluconazole-resistant C. albicans strain Can90 was provided
by theMassachusetts General Hospital. Yeast strains were grown in YPD
medium supplemented with 0.27mMuridine and selected using Nat at
a concentration of 200 mg/ml. Transformations were performed using
the lithium acetate method (27). Flipout of NatR gene from Cas9-
expressing Duet vector pV1025 was done by induction of flippase by
growth in Difco yeast carbon base with bovine serum albumin, and
screening for isolates that had lost the NatR gene. Filamentation
experiments were performed with yeast grown overnight in liquid
YPD, washed twice in RPMI 1640medium (cat. #22400-105, Life Tech-
nologies) supplemented with 10% FBS, and incubated in RPMI + 10%
FBS for the indicated time at a starting optical density (OD) of 0.1.
Growth curves were performed in a clear-bottom 96-well plate and
incubated with shaking at 30°C in a Tecan Saphire2 plate reader, read-
ing OD at 600 nm every 5 min for the indicated time. YPD-grown
overnight yeast cultures were used to inoculate these wells to an initial
ODof 0.05.CRISPR-mutagenized lociwere verified by sequence analysis
of PCRproducts amplified from the target locus and by restriction digest
where applicable.
Plasmids/DNA
Plasmids for CaCas9 Duet and Solo systems are listed in the Supple-
mentary Materials. The CaCas9 DNA was synthesized by BioBasic,
with codons optimized for expression in both C. albicans and Saccha-
romyces cerevisiae. All key components were verified by sequencing
and restriction analysis, and vector sequences will be provided upon re-
quest. Solo and/or Duet vectors (5 to 10 mg) were linearized by digestingWT
dcr1–/–
37°C 16°C
WT
MAL2p-SNF1
snf1-K81R
Glucose Maltose
A
B
C 16°C30°C37°C
D WT snf1-K81R
WT
snf1-K81R
Fig. 4. The Candida CRISPR system allows efficient isolation of muta-
tions in essential functions. (A) SC5314 of the indicated genotype was
grown at 37° or 16°C. (B) Strains were grown on YPD with the indicated car-
bon source at 37°C for 3 days. (C) Strains were grown in YPD at the indicated
temperatures. (D) Overnight YPD cultureswere diluted into RPMI + 10% fetal
bovine serum (FBS) and grown for 2 hours at 37°C. Scale bars, 5 mm.5 of 6
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ENO1 and/or the RP10 locus. Purified repair templates (3 mg) were
transformed along with the guide expression plasmids for the Solo
or Duet systems. Repair templates were generated with 60-bp oligo-
nucleotide primers containing 20-bp overlap at their 3′ ends centered
on the desired mutation point. Primers were extended by thermocycling
with ExTaq. Most guides were either immediately adjacent to or within
15 bp of the desired mutagenesis point. Phosphorylated and annealed
guide sequence–containing primers were ligated into CIP (calf intestinal
phosphatase)–treated BsmBI-digested parent vectors as depicted in Fig.
1C. Correct clones were identified by sequencing.
Computational analysis
We searched the diploid C. albicans genome sequence for matches to the
patterns N20(NGG) or (CCN)N20, and selected only sequences that over-
lapped with features found in the most recent gff file available from the
Candida Genome Database (C_albicans_SC5314_version_A22-s05-
m01-r03_features.gff), excluding the chromosomes themselves. We re-
moved any targets that have 6Ts in the 20 bp before the NGG, because
this would result in premature termination from Pol III promoters. Be-
cause matches 13 nucleotides proximal to a PAM sequence (NGG or
CCN) would also result in a cut to the genome, we searched all sites that
would be targeted by each 13 bp proximal to any PAMmotif in the ge-
nome (Supplementary Data Files). We also did the same search with 12
bp for a stricter cutoff. We annotated and classified the target sequences
based on the number of genes and intergenic regions they targeted.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/
full/1/3/e1500248/DC1
CaCas9 protein sequence
Fig. S1. Recyclable Solo system vector pV1200 permits serial mutagenesis.
Fig. S2. Candida CRISPR-Duet system requires Cas9, sgRNA expression, and a mutagenic repair
template.
Fig. S3. Candida CRISPR-Solo system requires a mutagenic repair template, but does not re-
quire selection for system components.
Fig. S4. Candida CRISPR permits the isolation of homozygous mutants at multiple loci, includ-
ing MtlA1, Mtla2, TPK2, and DCR1.
Fig. S5. Mutation of CDR1 and CDR2 creates pleiotropic drug sensitivity.
Fig. S6. Mutation of SNF1 in Candida.
Table S1. Plasmids used in this study.
Supplementary Data Files (separate zip file)REFERENCES AND NOTES
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